Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) Equity Ratio (2019 - 2023)

Alx Oncology Holdings' Equity Ratio history spans 5 years, with the latest figure at 0.77 for Q3 2023.

  • For Q3 2023, Equity Ratio fell 15.12% year-over-year to 0.77; the TTM value through Sep 2023 reached 0.77, down 15.12%, while the annual FY2022 figure was 0.86, 9.98% down from the prior year.
  • Equity Ratio for Q3 2023 was 0.77 at Alx Oncology Holdings, down from 0.86 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.99 in Q4 2020 and bottomed at 6.62 in Q4 2019.
  • The 5-year median for Equity Ratio is 0.91 (2022), against an average of 0.3.
  • The largest annual shift saw Equity Ratio skyrocketed 217.45% in 2021 before it dropped 15.12% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 6.62 in 2019, then surged by 114.9% to 0.99 in 2020, then decreased by 3.13% to 0.95 in 2021, then dropped by 9.98% to 0.86 in 2022, then dropped by 10.81% to 0.77 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Equity Ratio are 0.77 (Q3 2023), 0.86 (Q2 2023), and 0.86 (Q1 2023).